FDA Office of Prescription Drug Promotion Issues Warning Letter to ImmunityBio
March 25, 2026
March 25, 2026
WASHINGTON, March 25 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to ImmunityBio Inc. from its Office of Prescription Drug Promotion:
* * *
Recipient: Richard Adcock, President and Chief Executive Officer, ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA 90232, United States
Issuing Office: The Office of Prescription Drug Promotion (OPDP), United States
RE: BLA 76133 . . .
* * *
Recipient: Richard Adcock, President and Chief Executive Officer, ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA 90232, United States
Issuing Office: The Office of Prescription Drug Promotion (OPDP), United States
RE: BLA 76133 . . .